Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2017-11-10 Director's Dealing
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an official notification identified by the 'RNS Number' header. The content explicitly details a 'Notification of Transaction by Directors/PDMRs' concerning the purchase of shares by Nigel Theobald, who is the CEO and Director. This directly matches the definition of Director's Dealing (insider trades). The filing code for this specific type of insider transaction report is DIRS.
2017-11-10 English
Results of latest nuvec pre-clinical study
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement. The content details the 'Results of latest nuvec® pre-clinical study' conducted by N4 Pharma Plc, presenting scientific findings, conclusions, and future plans regarding their drug delivery system. This is a specific operational update concerning research results, not a full financial report (10-K or IR), a general earnings release (ER), or a management discussion (MDA). Since it is a specific announcement released via the RNS system that doesn't fit perfectly into other categories like DIV, DIRS, or CAP, the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly branded as an RNS release.
2017-11-08 English
Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
Earnings Release Classification · 1% confidence The document is an earnings release from Verona Pharma plc for the third quarter ended September 30, 2017. It contains key financial highlights (cash position, operating loss, loss per share) and operational updates (clinical trial progress). While it mentions that an electronic copy of the interim results will be made available, the document itself provides the substantive financial data and analysis for the quarter, fitting the definition of an Earnings Release (ER). 9M 2017
2017-11-07 English
Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
Regulatory Filings Classification · 1% confidence The document is a press release issued by Verona Pharma plc via GlobeNewswire on November 7, 2017. It announces an update regarding the enrollment progress and expected timeline for top-line data from their ongoing Phase 2b clinical study for the drug RPL554 for COPD treatment. This type of announcement, which provides operational updates, clinical trial progress, and forward-looking statements, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, the most appropriate classification for a press release detailing operational/clinical progress is 'Earnings Release' (ER), as these often accompany or precede formal earnings reports and contain key operational highlights. Given the content focuses heavily on clinical trial milestones and data timing, ER is the best fit among the provided options for a company update press release.
2017-11-07 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with "RNS Number : 4349V" and contains the standard format for a TR-1 notification, which is a regulatory filing concerning changes in major shareholdings. This directly corresponds to the definition for Major Shareholding Notification (MRQ). Although RNS is a general category, MRQ is more specific and accurate for a TR-1 form detailing ownership changes crossing a threshold.
2017-11-02 English
Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
Report Publication Announcement Classification · 1% confidence The document explicitly states that Verona Pharma plc "announces today that it will report its financial results for the three months ended September 30, 2017 on Tuesday, November 7, 2017." It then details the time and dial-in information for the conference call to discuss these results. This structure—announcing the date of an upcoming earnings report and scheduling a call—is characteristic of an Earnings Release (ER) or a precursor announcement. However, since the document is very short (3688 chars) and its primary function is to announce *when* the results will be released and *how* to listen to the subsequent call, it fits the definition of an announcement regarding the release of financial results. The closest specific category for announcing the release of financial results is 'Earnings Release' (ER), which typically covers the initial announcement of periodical financial results. If the document contained the actual results, it would be ER, but since it only announces the date and call details, it is a strong indicator of an ER announcement. Given the options, ER is the most appropriate classification for an announcement detailing the timing of quarterly results release and conference call details.
2017-10-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.